NEUROprotection Via optimizINg Cerebral Blood Flow afTer cArdiaC arresT (NEURO-INTACT) Study

Last updated: May 13, 2025
Sponsor: National University Hospital, Singapore
Overall Status: Active - Recruiting

Phase

N/A

Condition

N/A

Treatment

Individualized blood pressure strategy

Clinical Study ID

NCT05679739
NEURO-INTACT
  • Ages 21-79
  • All Genders

Study Summary

This single-center proof of concept study aims to assess the efficacy of a blood pressure strategy targeting person- and time-specific cerebral blood flow compared with standard-of-care using neuron-specific enolase as a quantitative biomarker of brain injury. Our central hypothesis is that an individualized blood pressure strategy targeting cerebral perfusion will reduce the extent of brain injury as indicated by changes in levels of neuron-specific enolase from baseline at 72 hours. To test this hypothesis, we will recruit 49 patients to an individualized blood pressure management strategy targeting cerebral blood flow, where optimal blood pressure will be serially calculated by the ICM+ brain monitoring software (Cambridge, UK) using inputs from transcranial Doppler ultrasound and near-infrared spectroscopy.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. At least 21 years of age

  2. Comatose defined as not being able to obey verbal commands and no verbal response topain after sustained ROSC.

Exclusion

Exclusion Criteria:

  1. ≥ 80 years old at time of enrolment

  2. Pregnant patients

  3. Limitations of care or life support therapy withdrawn within 24 hours of admission

Study Design

Total Participants: 49
Treatment Group(s): 1
Primary Treatment: Individualized blood pressure strategy
Phase:
Study Start date:
August 29, 2023
Estimated Completion Date:
August 31, 2026

Connect with a study center

  • National University Heart Centre, Singapore

    Singapore,
    Singapore

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.